Genomic Characterization CS-MATCH-0007 Arm C1

NCI-MATCH Clinical Trial (EAY131). The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm C1 is one of the treatment sub-protocols within the NCI-MATCH Clinical Trial (EAY131) where patients with MET amplification are treated with Crizotinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.]]>
Patients must fulfill all applicable eligibility criteria outlined in the MATCH Master Protocol.]]>

NCI-MATCH临床试验（EAY131）。本研究旨在明确与患者癌症中检出的特异性基因组改变相匹配的靶向治疗的应答与耐药分子机制。C1组是NCI-MATCH临床试验（EAY131）内的一项治疗子方案，针对MET扩增的患者使用克唑替尼（Crizotinib）进行治疗。该子方案属于CS-MATCH-0007方案所纳入的治疗组之一，将为该项目提供包括肿瘤组织DNA与全血在内的样本资源。]]>
患者须满足MATCH总方案中列明的所有适用入选标准。]]>